Evidence map›Paper›PMID 39630114›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Programmable Multiplexed Nucleic Acid Detection by Harnessing Specificity Defect of CRISPR-Cas12a.

Xin Guan, Rui Yang, Jiongyu Zhang, Jeong Moon, Chengyu Hou, Chong Guo, Lori Avery, Danielle Scarola, Daniel S Roberts, Rocco LaSala and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. SDS-CRISPR for Single-Nucleotide Variant Detection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xin GuanDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Rui YangDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Jiongyu ZhangDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Jeong MoonDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Chengyu HouDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Chong GuoDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Lori AveryDepartment of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Danielle ScarolaDivision of Otolaryngology-Head & Neck Surgery, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Daniel S RobertsDivision of Otolaryngology-Head & Neck Surgery, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Rocco LaSalaDepartment of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.
Changchun LiuDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, Connecticut, 06030, USA.ORCID https://orcid.org/0000-0002-4931-986X

Funding

Using human skin grafted mice to identify biomarkers of exposure and study effects of radiation on skinU01AI148306 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI CLARK, RACHAEL ANN · 2020 to 2024
$2.7M
Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of CareU01CA269147 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Changchun Liu · 2022 to 2026
$2.6M
NCI NIH HHS U01 CA269147NIAID NIH HHS U01 AI148306NIH HHS U01AI148306NIH HHS U01CA269147
6 · The paper itself

Abstract

CRISPR-Cas12a works like a sophisticated algorithm in nucleic acid detection, yet its challenge lies in sometimes failing to distinguish targets with mismatches due to its specificity limitations. Here, the mismatch profiles, including the quantity, location, and type of mismatches in the CRISPR-Cas12a reaction, are investigated and its various tolerances to mismatches are discovered. By harnessing the specificity defect of the CRISPR-Cas12a enzyme, a dual-mode detection strategy is designed, which includes approximate matching and precise querying of target sequences and develop a programmable multiplexed nucleic acid assay. With the assay, 14 high-risk human papillomavirus (HPV) subtypes are simultaneously detected, collectively responsible for 99% of cervical cancer cases, with attomolar sensitivity. Specifically, the assay not only distinguishes HPV16 and HPV18, the two most common subtypes but also detects 12 other high-risk pooled HPV subtypes. To enable low-cost point-of-care testing, the assay is incorporated into a paper-based microfluidic chip. Furthermore, the clinical performance of the paper-based microfluidic chip is validated by testing 75 clinical swab samples, achieving performance comparable to that of PCR. This programmable multiplexed nucleic acid assay has the potential to be widely applied for sensitive, specific, and simultaneous detection of different pathogens.

Indexed as

CRISPR-Cas SystemsNucleic AcidsBacterial ProteinsCRISPR-Associated ProteinsDNA, ViralEndodeoxyribonucleasesFemaleHuman papillomavirus 16HumansPapillomaviridaePapillomavirus InfectionsSensitivity and SpecificityUterine Cervical NeoplasmsBacterial ProteinsCas12a proteinCRISPR-Associated ProteinsDNA, ViralEndodeoxyribonucleasesNucleic Acidsapproximate pattern matchingCRISPR‐Cas12aHR‐HPV detectionpaper‐based microfluidic chipprecise querying

Identifiers

PMID39630114
PMCPMC11775522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.